<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01790282</url>
  </required_header>
  <id_info>
    <org_study_id>E2 luteal support in ICSI</org_study_id>
    <nct_id>NCT01790282</nct_id>
  </id_info>
  <brief_title>Is Adding E2 to P4 Luteal Support In High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Outcome? RCT</brief_title>
  <official_title>Is E2 Luteal Support in High Responder Long Gn-RH Agonist ICSI Cycles Detrimental to Cycle Outcome ? A Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura Integrated Fertility Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura Integrated Fertility Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study if supporting luteal phase of high responder (high egg production or high Estradiol
      level) long Gn_Rh agonist protocol ICSI/IVF cycle by combined Estradiol and progesterone
      impairs or improves outcome in terms of pregnancy and implanation rates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The role of estradiol (E2) luteal support is still debated after more than a decade of use.
      Two recent met analyses (Gelbaya et al 2008) &amp;(Jee et al 2010)( ) has shown that the addition
      of E2 to P4 for luteal phase support in IVF/ICSI cycles has no beneficial effect on pregnancy
      rates. However they commented that the data in the literature are, limited and heterogeneous,
      precluding the extraction of clear and definite conclusions. Previous met analysis ( Pritts
      and Atwood 2002 ) and an update (Fatemi et al 2007 ) and subsequent randomized trials (
      Ghanem et al 2009 , Var et al 2011 ) reported beneficial effects of adding E2 to luteal P4
      support. Recent retrospective studies have shown that high response in terms of excess egg
      production ( &gt;15 . ) and or high E2 (Chen et al 2007,Kyrou et al 2009, Sunkara 2011 ) are
      detrimental to cycle outcome. This prospective randomized trial aims to study whether adding
      E2 to P4 luteal support in high ovarian responders is detrimental to cycle outcome or not

      --------------- Gelbaya TA, KyrgiouM, Tsoumpou I, Nardo LG. The use of estradiol for luteal
      phase support in in vitro fertilization/intracytoplasmic sperminjec- tion cycles: a
      systematic review and meta-analysis. Fertil Steril 2008;90: 2116-25.

      Jee BC, Suh CS, Kim SH, Kim YB, Moon SY. Effects of estradiol supplementation during the
      luteal phase of in vitro fertilization cycles: a meta-analysis Fertil Steril. 2010
      Feb;93(2):428-36

      Pritts EA, Atwood AK. Luteal phase support in infertility treatment: a meta-analysis of
      randomized trials. Hum Reprod 2002;17:2287-99 Fatemi HM, Popovic-Todorovic B, Papanikolaou E,
      Donoso P,Devroey P. An update of luteal phase support in stimulated IVF cycles.Hum Reprod
      Update 2007;13:581.

        -  Ghanem M E., Ehab E. Sadek, Elboghdady L. A.. Helal A S, Gamal Anas, Eldiasty A Bakre N
           I., Houssen M .The effect of luteal phase support protocol on cycle outcome and luteal
           phase hormone profile in long agonist protocol intracytoplasmic sperm injection cycles:
           a randomized clinical trial , Fertility and Sterility 2009 92: 486-493

      Var T, Tonguc EA, DoÄŸanay M, Gulerman C, Gungor T, Mollamahmutoglu L. A comparison of the
      effects of three different luteal phase support protocols on in vitro fertilization outcomes:
      a randomized clinical trial. Fertil Steril. 2011 Mar 1;95(3):985-9.

      van der Gaast, Eijkemans JB, de Boer EJ, Burger CW , van Leeuwen FE, Fauser BCJM , and
      Macklon NS Optimum number of oocytes for a successful first IVF treatment cycle Reproductive
      BioMedicine Online 2006 ; 13: 476-480

      Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A.
      Association between the number of eggs and live birth in IVF treatment: an analysis of 400
      135 treatment cycles. Hum Reprod 2011; 26: 1768-1774

      Chen QJ, Sun XX, Li L, Gao XH, Wu Y, Gemzell-Danielsson K, Cheng LN Effects of ovarian high
      response on implantation and pregnancy outcome during controlled ovarian hyperstimulation
      (with GnRH agonist and rFSH). Acta Obstet Gynecol Scand. 2007;86:849-54 Kyrou D.,
      Popovic-Todorovic B., Fatemi H.M1, Bourgain C, Haentjens P., Van Landuyt L., and. Devroey P
      Does the estradiol level on the day of human chorionic gonadotrophin administration have an
      impact on pregnancy rates in patients treated with rec-FSH/GnRH antagonist? Hum Reprod 2009,
      2902-2909,
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cycle pregnancy rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>pregnancy rate per started cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>implantation rate, multiple pregnancy rate, ongoing pregnancy rate ,live birth rate</measure>
    <time_frame>6 weeks</time_frame>
    <description>implantation rate,multible pregnancy rate, abortion rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>IVF</condition>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>estradiole - progesterone arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cases are given estradiole valerate 2mg 3 times /day from day of ovum pick up until the time of pregnancy test two weeks together with daily IM injection of 100 progesterone starting . Single intramuscular 0.1 mg decapeptyl are given on day of transfer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone only arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient are given 100 mg progesterone daily starting on day of pickup plus single dose of decapeptyl 0.1 mg on day of embryo transfer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>estradiol plus progesterone 100 mg IM injection</intervention_name>
    <description>estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET</description>
    <arm_group_label>estradiole - progesterone arm</arm_group_label>
    <other_name>estradiole valerate 2mg,</other_name>
    <other_name>Prontogest 100 mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone IM of 100 mg</intervention_name>
    <description>Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer</description>
    <arm_group_label>estradiole - progesterone arm</arm_group_label>
    <arm_group_label>Progesterone only arm</arm_group_label>
    <other_name>prontogest 100 mg ampoles</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          -  age&lt;40 years,

          -  first ICSI cycle,

          -  third day FSH&lt; 10 mIU/mL,

          -  serum E2 level on day of hCG administration &lt;4,000 pg/mL,

          -  number of ova obtained &gt;15

        Exclusion Criteria:

          -  age 40 years or more,

          -  basal FSH 10 mIU/mL or more ,

          -  eggs retrieved 15 or less ,

          -  E2 level on day of hCG administration 4000 or more pg/ mL or more,

          -  repeat ICSI , need for PGD, presence of myoma , hydrosalpinx (unless disconnected)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>mohamad E GHanem, MD</last_name>
    <phone>00201223366955</phone>
    <email>meghanem87@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mansoura Integrated fertility center</name>
      <address>
        <city>Mansoura</city>
        <state>Dekahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mansoura integrated fertility center</name>
      <address>
        <city>Mansoura</city>
        <state>Dekahlia</state>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mohamad E Ghanem, MD</last_name>
      <phone>00201223366955</phone>
      <email>meghanem87@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Gelbaya TA, Kyrgiou M, Tsoumpou I, Nardo LG. The use of estradiol for luteal phase support in in vitro fertilization/intracytoplasmic sperm injection cycles: a systematic review and meta-analysis. Fertil Steril. 2008 Dec;90(6):2116-25. doi: 10.1016/j.fertnstert.2007.10.053. Epub 2008 Jan 7. Review.</citation>
    <PMID>18178194</PMID>
  </reference>
  <reference>
    <citation>Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J, Coomarasamy A. Association between the number of eggs and live birth in IVF treatment: an analysis of 400 135 treatment cycles. Hum Reprod. 2011 Jul;26(7):1768-74. doi: 10.1093/humrep/der106. Epub 2011 May 10.</citation>
    <PMID>21558332</PMID>
  </reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 8, 2013</study_first_submitted>
  <study_first_submitted_qc>February 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2013</study_first_posted>
  <last_update_submitted>February 12, 2013</last_update_submitted>
  <last_update_submitted_qc>February 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 15, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura Integrated Fertility Center</investigator_affiliation>
    <investigator_full_name>Mohamad Elsaid Ghanem</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>luteal support</keyword>
  <keyword>high responder</keyword>
  <keyword>ICSI</keyword>
  <keyword>ivf</keyword>
  <keyword>cycle outcome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

